Vision & Strategy
Our vision is to build the largest, independent vaccine company either through bringing products to market from our own research and development pipeline or through acquisition and in-licensing transactions.Our pipeline specifically targets diseases that currently lack optimal vaccines such as cholera, hepatitis A and HIV.
Our primary focus is on the development and commercialization of vaccines for the overlooked, traveler segment. We have vaccines either commercially available or in development to protect travelers from typhoid, cholera and hepatitis A.
Travel vaccines are not only important for the developed world, but these vaccines can also be of benefit for the developing world to protect against endemic infectious disease. We are working to ensure our vaccines will also be applicable in the developing world.
Research & Development
PaxVax has developed and in-licensed different technologies to help advance vaccine candidates to the clinic and eventually to market. The company has successfully brought four vaccine candidates from the bench into clinical trials in humans. PaxVax has worked successfully on both bacterial and viral vaccines as well as on different strategic approaches to vaccine development such as inactivation, live-attenuation and virosome technology. A number of PaxVax vaccine candidates utilize new technologies that the company has pioneered, such as Ad4/Ad7 vectors and the A549 cell substrate.
Today, PaxVax maintains research and development and Good Manufacturing Practice (GMP) facilities in San Diego, California, USA, and Thörishaus, Switzerland. These facilities include:
• Early-stage preclinical R&D
• Clinical study support
• GMP drug product manufacturing
• Drug substance sterile fill and finish
• Packaging infrastructure
PaxVax manufactures Vivotif® for all markets in its GMP-certified facility in Thörishaus, Switzerland.
More information is available at www.PaxVax.com.